NeuroSense Investor Relations

NASDAQNRSN

Investor Relations

About Us

Pipeline

Media

Investor RelationsClick here to open mobile navigation

Recent News

Investor Alerts

Dec 2, 2024

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry...

Nov 21, 2024

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce...

Oct 28, 2024

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense...

Latest Events

No events to display

Investor Presentation

Download PDF

Board Diversity Matrix

Download PDF

Investor Relations

Home

Research

About

Publications